Leading the future of Mold Toxicity treatment
Our work combines the latest clinical insights and real-world outcomes to develop the most advanced treatments available today.
Dr. Ritchie Shoemaker
Dr. Scott McMahon
Dr. Margaret DiTulio
key research areas:
Identifying biomarkers for Mold Toxicity exposure
Developing next-gen precision treatments
Investigating the long-term effects of mold exposure
Our approach
We bridge the gap between science & patient care
The health impacts of mold are often misunderstood and misdiagnosed. MoldCo is changing that by pioneering research into the biological mechanisms of Mold Toxicity, while advancing awareness of the issue.
Our clinical model connects research, expert provider training, and real-world patient outcomes so patients can move from confusion to an evidence-based care path.
Hear from the minds shaping mold care
Backed by research and grounded in clinical practice, these conversations explore the science transforming patient outcomes.
“Three decades of CIRS research have helped define published diagnostic markers, treatment sequencing, and a clearer clinical language for water-damaged building illness.”
Research context from Dr. Ritchie Shoemaker's published work
Our network
A network dedicated to mold treatment science
Following Dr. Shoemaker's pioneering work, MoldCo's research efforts are led by some of the top clinicians and scientists in the field of environmental medicine.
Research pioneer
Dr. Ritchie Shoemaker
Founder of CIRS Research
Medical director
Dr. Scott McMahon
Medical Director, CMM
Clinical leader
Dr. Margaret DiTulio
Clinical Director, Regenix Healing
Research network
Peer reviewed research from our team
Research we've authored or contributed to in the field of Chronic Inflammatory Response Syndrome (CIRS).
RNA-Seq on Patients with Chronic Inflammatory Response Syndrome (CIRS)
Dr. Ritchie Shoemaker
An Evaluation of Alternate Means to Diagnose Chronic Inflammatory Response Syndrome and Determine Prevalence
Dr. Scott McMahon
Diagnostic Process for Chronic Inflammatory Response Syndrome (CIRS): A Consensus Statement Report
Dr. Ritchie Shoemaker, Dr. Scott McMahon
Advance mold treatment science with us
Talk with MoldCo about clinical research, evidence review, and provider collaboration.
95% of tracked patients report fewer symptoms in their first 30 days¹
Start with a provider who understands what you're going through.
Disclaimer
Medical care is provided by licensed care providers. MoldCo provides technology and administrative services and does not practice medicine.
The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment.
Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). Some medicines are FDA-approved for other conditions and prescribed “off-label” for mold-related conditions. Each product page states its FDA status.
Results vary. No clinician or company can promise that treatment will improve your symptoms. Seek evaluation and treatment from your healthcare providers.
MoldCo services are not for emergencies. If you think you have a medical emergency, call 911 or go to the nearest emergency room.